Why we should be using apo-B over other lipid measurements

Making the case for using apoB in primary prevention (people without known ASCVD, like heart attack, stroke, or prior events) is strong and growing, based on expert opinion, observational data, Mendelian randomization (genetic evidence showing causality), and discordance analyses. While major U.S. guidelines (like the 2026 ACC/AHA) still center on LDL-C for broad primary prevention, many lipid specialists argue apoB should be the preferred or routine marker—here's why:

• ApoB directly measures the true culprit: Each atherogenic particle (LDL, VLDL remnants, Lp(a)) has one apoB molecule. ApoB counts the number of harmful particles entering artery walls, while LDL-C measures only the cholesterol mass inside them. In metabolic conditions (common in primary prevention: obesity, prediabetes, high triglycerides), particles are often small/dense with less cholesterol per particle—LDL-C underestimates risk, but apoB captures it accurately.

• Superior risk prediction in studies: Large observational cohorts, discordance analyses (e.g., LDL-C "normal" but apoB high), and meta-analyses show apoB outperforms LDL-C and non-HDL-C for predicting first-time ASCVD events. For example, discordantly high apoB links to higher future events, even when LDL-C looks fine.

• Genetic (Mendelian randomization) evidence: These studies use naturally occurring gene variants to mimic lifelong exposure. They consistently show apoB (or equivalent particle number) causally drives ASCVD risk more strongly than LDL-C alone. Lowering apoB genetically reduces events proportionally, supporting it as the core driver across the risk spectrum, including primary prevention.

• Practical advantages for screening: ApoB is standardized, doesn't require fasting (unlike some triglyceride-dependent calculations), and is widely available/inexpensive in many labs. It's stable over time and better reflects lifetime exposure in younger adults or those with family history—key for primary prevention where early intervention prevents decades of damage.

• Expert consensus pushes for broader use: Groups like the National Lipid Association (NLA) propose apoB thresholds for primary prevention (e.g., <90 mg/dL for intermediate risk, aligning with non-HDL-C). European (ESC/EAS) guidelines allow apoB as a primary target in many cases (Class I in high-triglyceride/diabetes/obesity groups). Canadian guidelines have long favored apoB over LDL-C when triglycerides are elevated. Experts like Allan Sniderman, Salim Virani, and others argue apoB is the "best single marker" and should be routine, as discordance affects ~20% of people and leads to undertreatment if ignored.

• Potential to prevent more events: Modeling and real-world data suggest using apoB could reclassify risk upward in millions (especially with metabolic issues), leading to earlier statins or intensification and averting events that LDL-C-based approaches miss.

In primary prevention, apoB shines where traditional metrics falter—metabolic syndrome, family history, borderline risk, or South Asian ancestry. While we await large RCTs targeting apoB goals (the main guideline hesitation), the weight of causal, predictive, and practical evidence makes a compelling case for routine apoB testing in adults, especially those with any cardiometabolic red flags. Many preventive cardiologists already use it this way—discuss it with your doctor if your profile fits!